Interferon alfa-2b

From Wikipedia, the free encyclopedia
  (Redirected from Interferon alfa 2b)
Jump to navigation Jump to search
Interferon alfa-2b
Clinical data
License data
  • US: C (Risk not ruled out)
Routes of
Subcutaneous, intramuscular
ATC code
Legal status
Legal status
  • none
ECHA InfoCard100.208.165 Edit this at Wikidata
 ☒N☑Y (what is this?)  (verify)

Interferon alfa 2b is an antiviral or antineoplastic drug, that was originally discovered in the laboratory of Charles Weissmann at the University of Zurich. It was developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.

This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.

Interferon alfa-2b products[1]
Product Manufacturer Features Special uses
Alpharona Pharmaclon
Intron-A/IntronA Schering-Plough
Realderon Teva
Reaferon EC GNC Vector
Reaferon EC-Lipint Vector-Medica liposomal
Infagel Vector-Medica ointment
Recolin Vector-Medica
Altevir Bioprocess subsidiary liquid, free of HSA
Kipferon Alfarm combination with IgM, IgA, IgG
Giaferon A/S Vitafarma
Genferon Biocad
Opthalamoferon Firn-M with dimedrol eye infections

See also[edit]


  1. ^ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2.

External links[edit]